Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach
Following a rough few weeks, the revolving door at the executive suite to Immunomedics $IMMU is turning once more.
After the market closed on Monday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
